Search Results - James G. Christensen

Refine Results
  1. 1
    An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

    An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis by Marion Zillhardt, James G. Christensen, Ernst Lengyel

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

    A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin by C. Patrick, Erik Schaefer, James G. Christensen, Ravi Salgia

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency by Ultan McDermott, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, Jeff Settleman

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Targeting Kras <sup>g12c</sup> ‐mutant cancer with a mutation‐specific inhibitor

    Targeting Kras <sup>g12c</sup> ‐mutant cancer with a mutation‐specific inhibitor by James G. Christensen, Peter Olson, Tina M. Briere, Clotilde Wiel, Martin O. Bergö

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

    HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation by David Liska, Chin‐Tung Chen, Thomas Bachleitner‐Hofmann, James G. Christensen, Martin R. Weiser

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice

    Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice by Barbara Sennino, Toshina Ishiguro‐Oonuma, Brian J. Schriver, James G. Christensen, Donald M. McDonald

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

    Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy by John M.L. Ebos, Christina R. Lee, James G. Christensen, Anthony J. Mutsaers, Robert S. Kerbel

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    MET Activation Mediates Resistance to Lapatinib Inhibition of <i>HER2</i>-Amplified Gastric Cancer Cells

    MET Activation Mediates Resistance to Lapatinib Inhibition of <i>HER2</i>-Amplified Gastric Cancer Cells by Chin‐Tung Chen, Hyaehwan Kim, David Liska, Sizhi Paul Gao, James G. Christensen, Martin R. Weiser

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab

    Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab by Lori S. Hart, Nathan G. Dolloff, David T. Dicker, Constantinos Koumenis, James G. Christensen, Adda Grimberg, Wafik S. El‐Deiry

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

    Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma by Sophie de Boüard, Paulette Herlin, James G. Christensen, Edwige Lemoisson, Pascal Gauduchon, Éric Raymond, Jean‐Sébastien Guillamo

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

    Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis by John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz, Georg A. Bjarnason, James G. Christensen, Robert S. Kerbel

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

    Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors by Jie Qi, Michele McTigue, Andrew M. Rogers, Eugene Lifshits, James G. Christensen, Pasi A. Jänne, Jeffrey A. Engelman

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

    Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells by Seema Agarwal, Cynthia Zerillo, J Kolmakova, James G. Christensen, L N Harris, David L. Rimm, Michael P. DiGiovanna, David F. Stern

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

    Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway by Alexis B. Cortot, Claire E. Repellin, Takeshi Shimamura, Marzia Capelletti, Kreshnik Zejnullahu, Dalia Ercan, James G. Christensen, Kwok‐Kin Wong, Nathanael S. Gray, Pasi A. Jänne

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    <i>In Vivo</i> Activity of Combined PI3K/mTOR and MEK Inhibition in a <i>KrasG12D</i>;<i>Pten</i> Deletion Mouse Model of Ovarian Cancer

    <i>In Vivo</i> Activity of Combined PI3K/mTOR and MEK Inhibition in a <i>KrasG12D</i>;<i>Pten</i> Deletion Mouse Model of Ovarian Cancer by Kathryn M. Kinross, Daniel V. Brown, Margarete Kleinschmidt, Susan Jackson, James G. Christensen, Carleen Cullinane, Rodney J. Hicks, Ricky W. Johnstone, Grant A. McArthur

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

    Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells by Christina Schönherr, Kristina Ruuth, Sattu Kamaraj, C-L Wang, Hong‐Ling Yang, Valérie Combaret, Anna Djos, Tommy Martinsson, James G. Christensen, Ruth H. Palmer, Bengt Hallberg

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models

    Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models by Cathy C. Zhang, Zhengming Yan, Qing Zong, Douglas D. Fang, Cory L. Painter, Qin Zhang, Enhong Chen, Maruja E. Lira, Annette John-Baptiste, James G. Christensen

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib

    MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib by Manik Chahal, Yaoxian Xu, David Lesniak, Kathryn Graham, Konrad S. Famulski, James G. Christensen, Manish K. Aghi, Amanda Virtuoso Jacques, David J. Murray, Siham Sabri, Bassam Abdulkarim

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

    HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors by Farbod Shojaei, Joseph H. Lee, Brett H. Simmons, Anthony Wong, Carlos O. Esparza, Pamela A. Plumlee, Junli Feng, Albert Stewart, Dana D. Hu‐Lowe, James G. Christensen

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

    The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy by David M. Briere, Niranjan Sudhakar, David M. Woods, Jill Hallin, Lars D. Engstrom, Ruth Aranda, Harrah Chiang, Andressa L. Sodré, Peter Olson, Jeffrey S. Weber, James G. Christensen

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: